Table 3 Number of FDA-approved and clinically tested drugs present in both drug-target datasets across the four investigated cancers.

From: Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures

Dataset

DrugBank Approved

DrugBank Clinical trials

DrugCentral Approved

DrugCentral Clinical trials

BRCA

26/1346 (1.93%)

182/1346 (13.52%)

14/638 (2.19%)

115/638 (18.02%)

LIHC

5/1346 (0.37%)

50/1346 (3.71%)

1/638 (0.16%)

35/638 (5.49%)

PRAD

13/1346 (0.97%)

134/1346 (9.96%)

7/638 (1.10%)

84/638 (13.17%)

KIRC

8/1346 (0.60%)

44/1346 (3.26%)

3/638 (0.47%)

25/638 (3.91%)

  1. The percentage for the number of FDA-approved/clinically investigated drugs for each cancer type over the total number of drugs present in the drug-target dataset is reported between parentheses.
Back to article page